Zacks: BioLife Solutions Inc (BLFS) Given Consensus Rating of “Strong Buy” by Brokerages
BioLife Solutions Inc (NASDAQ:BLFS) has earned an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus target price of $19.00 for the company and are forecasting that the company will post $0.04 earnings per share for the current quarter, according to Zacks. Zacks has also given BioLife Solutions an industry rank of 121 out of 255 based on the ratings given to related companies.
A number of analysts have recently issued reports on BLFS shares. Maxim Group set a $9.00 price target on BioLife Solutions and gave the stock a “buy” rating in a research note on Monday, April 30th. ValuEngine raised BioLife Solutions from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 4th. B. Riley started coverage on BioLife Solutions in a research note on Thursday, June 7th. They issued a “buy” rating and a $14.00 price target on the stock. Finally, Northland Securities reaffirmed a “buy” rating and issued a $18.00 price target on shares of BioLife Solutions in a research note on Friday.
A number of institutional investors have recently made changes to their positions in BLFS. Wells Fargo & Company MN purchased a new position in BioLife Solutions during the fourth quarter worth approximately $111,000. Millennium Management LLC lifted its position in BioLife Solutions by 901.6% during the fourth quarter. Millennium Management LLC now owns 182,550 shares of the medical equipment provider’s stock worth $1,095,000 after buying an additional 164,324 shares in the last quarter. Bank of Montreal Can purchased a new stake in BioLife Solutions in the second quarter valued at $114,000. Essex Investment Management Co. LLC raised its position in BioLife Solutions by 29.4% in the second quarter. Essex Investment Management Co. LLC now owns 295,728 shares of the medical equipment provider’s stock valued at $3,374,000 after purchasing an additional 67,182 shares during the period. Finally, Acadian Asset Management LLC purchased a new stake in BioLife Solutions in the second quarter valued at $569,000. Hedge funds and other institutional investors own 16.34% of the company’s stock.
Shares of NASDAQ:BLFS opened at $20.54 on Tuesday. The company has a market capitalization of $278.94 million, a PE ratio of -97.81 and a beta of 0.64. BioLife Solutions has a 1 year low of $3.68 and a 1 year high of $22.86.
BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, August 9th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.01. The firm had revenue of $5.18 million for the quarter, compared to analyst estimates of $5.20 million. BioLife Solutions had a return on equity of 2.86% and a net margin of 1.76%. research analysts predict that BioLife Solutions will post 0.14 EPS for the current fiscal year.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.
See Also: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.